Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures.
Typical methods used for encapsulating antisense oligodeoxynucleotides (ODN) and plasmid DNA in lipid vesicles result in very low encapsulation efficiencies or employ cationic lipids that exhibit unfavorable pharmacokinetic and toxicity characteristics when administered intravenously. In this study, we describe and characterize a novel formulation process that utilizes an ionizable aminolipid (1,2-dioleoyl-3-dimethylammonium propane, DODAP) and an ethanol-containing buffer system for encapsulating large quantities (0.15--0.25 g ODN/g lipid) of polyanionic ODN in lipid vesicles. This process requires the presence of up to 40% ethanol (v/v) and initial formulation at acidic pH values where the DODAP is positively charged. In addition, the presence of a poly(ethylene glycol)-lipid was required during the formulation process to prevent aggregation. The 'stabilized antisense-lipid particles' (SALP) formed are stable on adjustment of the external pH to neutral pH values and the formulation process allows encapsulation efficiencies of up to 70%. ODN encapsulation was confirmed by nuclease protection assays and (31)P NMR measurements. Cryo-electron microscopy indicated that the final particles consisted of a mixed population of unilamellar and small multilamellar vesicles (80--140 nm diameter), the relative proportion of which was dependent on the initial ODN to lipid ratio. Finally, SALP exhibited significantly enhanced circulation lifetimes in mice relative to free antisense ODN, cationic lipid/ODN complexes and SALP prepared with quaternary aminolipids. Given the small particle sizes and improved encapsulation efficiency, ODN to lipid ratios, and circulation times of this formulation compared to others, we believe SALP represent a viable candidate for systemic applications involving nucleic acid therapeutics.
Semple
S C
SC
Inex Pharmaceutical Corp., Burnaby, B.C., Canada. ssemple@inexpharm.com
Klimuk
S K
SK
Harasym
T O
TO
Dos Santos
N
N
Ansell
S M
SM
Wong
K F
KF
Maurer
N
N
Stark
H
H
Cullis
P R
PR
Hope
M J
MJ
Scherrer
P
P
D000818:Animals; D002412:Cations; D020285:Cryoelectron Microscopy; D004337:Drug Carriers; D000431:Ethanol; D005260:Female; D006863:Hydrogen-Ion Concentration; D008081:Liposomes / Q000138:chemical synthesis / Q000737:chemistry* / Q000493:pharmacokinetics; D009682:Magnetic Resonance Spectroscopy; D008563:Membrane Lipids / Q000737:chemistry; D051379:Mice; D008813:Mice, Inbred ICR; D017830:Octoxynol; D016376:Oligonucleotides, Antisense / Q000737:chemistry* / Q000627:therapeutic use; D010713:Phosphatidylcholines; D011092:Polyethylene Glycols; D015719:Single-Strand Specific DNA and RNA Endonucleases
D002412:Cations; D004337:Drug Carriers; D008081:Liposomes; D008563:Membrane Lipids; D016376:Oligonucleotides, Antisense; D010713:Phosphatidylcholines; D000431:Ethanol; D011092:Polyethylene Glycols; D017830:Octoxynol; C010942:1,2-distearoyllecithin; D015719:Single-Strand Specific DNA and RNA Endonucleases